NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Globe Newswire•24/07/2026•08:00 ET
0
Whiz Insights
- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe -
- Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, and TANDEM data -
Get started
Create a free account to read the full story.